A new form of a widely used opioid addiction treatment that is injected monthly instead of taken daily as a tablet was approved Thursday by the Food and Drug Administration. Experts say the eagerly anticipated new version of the drug may help patients reduce relapses, disrupt the treatment market, and possibly dispel misconceptions about the drug’s potential for abuse.

Indivior is the first company to gain approval for a monthly injection of buprenorphine. The company is best known for Suboxone, a daily formulation that combines buprenorphine with naloxone into a film that dissolves under the tongue.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I received my injection a couple of days ago, I have not experienced any withdrawal n it seems to be working. Wonderful not to take daily medication.

  • Sounds promising. There’s a mistake in your article though. With any bupe based product thete is still a required “detox period.” Bupe has a very high binding affinity to the mu-opioid receptor (even though its a partial agonist) and if taken too soon will cause precipitated withdrawal. This product will have a required detox period, although it will be shorter than vivatrols.

  • For someone who is a heroin addict for over 3 years and lost a brother to addiction this seems like a real option for me……i throwup instantly from the taste of suboxon film and can never detox long enough to get the vivitrol shot….🆘 i wish this was around years ago…..cant wait thank you

  • We pay anywhere from 150 to 300 per month for our doctors visit for the subxone films so will we have to pay that much or more for the injections monthly

  • Buprenorphine itself is a blocker – suboxone was made to prevent addicts injecting it. This is the kind of misinformation people spout off who know nothing. Please do some research before posting such an idiot comment.

Your daily dose of news in health and medicine

Privacy Policy